Sotorasib (AMG510/Sotorasib): New breakthroughs and medication guidelines for the treatment of KRAS mutated cancers

1. Analysis of common names and product names

Sotorasib (AMG510/Sotorasib) is the world's first approved KRAS G12C mutation inhibitor, and its trade names include Lumakras (US version) and Lumykras (EU version). The drug was developed by Amgen of the United States. In May 2021, the drug was acceleratedly approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC). In January 2025, it was further approved to be combined with panitumumab (panitumumab) to treat metastatic colorectal cancer (mCRC), marking the entry into the era of precision targeting in the treatment of KRAS mutated cancers.

xa0

2. Expansion of indications: breakthrough from lung cancer to colorectal cancer

1. Non-small cell lung cancer (NSCLC)

Sotorasiib is suitable for adult patients with locally advanced or metastatic NSCLC confirmed by FDA-approved testing to have KRAS G12C mutations, and must meet the conditions for progression after receiving at least one systemic therapy (such as chemotherapy, immunotherapy). The latest data in 2025 show that in the CodeBreaK 100 trial, single-agent treatment achieved an objective response rate (ORR) of 37.1%, a median progression-free survival (mPFS) of 6.8 months, and a median overall survival (mOS) of 12.5 months, which is significantly better than traditional chemotherapy regimens.

2. Metastatic colorectal cancer (mCRC)

In January 2025, the FDA approved sotoraxib combined with panitumumab (anti-EGFR monoclonal antibody) for patients with KRAS G12C mutated mCRC based on the results of the CodeBreaK 300 trial. This combination therapy has an ORR of 30%, a disease control rate (DCR) of 93%, and a median mPFS of 5.6 months in patients who have previously received chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan, providing a new option for this type of refractory patients.

Popular understanding: Sotolaxib is not suitable for all patients with lung cancer or colorectal cancer. It is targeted at people with specific gene mutations. Doctors will judge whether it is suitable based on the genetic test results.

xa0

3. Side Effect Management and Medication Safety

Common side effects include:

Diarrhea

muscle or joint pain

Disgusting

fatigue

abnormal liver function

cough

Serious side effects are rare but include pneumonia, severe liver toxicity, or persistent diarrhea. Blood parameters may include lymphopenia, decreased hemoglobin, or elevated liver enzymes.

Most side effects can be monitored and treated, and you should seek medical attention promptly if you experience any obvious discomfort. The doctor may pause the medication or adjust the dose to ensure safety.

xa0

4. Usage, dosage and medication compliance

1. Standard dosage and adjustments

Recommended dose: Take orally once daily960 mg (eight 120 mg tablets), swallow the whole tablet or disperse it in 120 mL of non-carbonated water for drinking.

Handling of missed doses: If you miss a dose ≤ 6 hours, take it immediately; if > 6 hours, skip the dose and take it as originally planned the next day. Do not double the dose to compensate.

Dose adjustment:Grade 3 adverse reactions (such as severe diarrhea, liver toxicity) require suspension of medication and reduction to 480 mg or 720 mg after recovery; if 240 mg cannot be tolerated, discontinue medication permanently.

xa0

5. Price Guide for Original Drugs and Generic Drugs

1. Original drug price

U.S. market:The price of 120 mg × 240 tablets is about RMB 80,000, and the price is high due to patent protection.

Hong Kong, China and Europe:The specification of 120mg×240 tablets is about more than 40,000 yuan (affected by exchange rate fluctuations).

2. Generic drug prices

Laos Lucius Pharmaceutical:The price of 120mg×56 tablets is about RMB 1,000;

Bangladesh Everest Pharmaceuticals:120 mg

3. Need for combination therapy: Colorectal cancer patients need to be combined with panitumumab, and the overall treatment cost needs to be evaluated.

xa0

6. Mechanism of action: crackingKRAS’ “undruggable” problem

KRAS G12C mutations lead to sustained activation of the protein and drive tumor proliferation. Sotorasibu binds to the "Switch-II pocket" of the mutant protein to form an irreversible covalent bond, locking KRAS in an inactive GDP-bound state, thus blocking the downstream RAS-MAPK signaling pathway. Its unique advantages include:

High selectivity: only targets KRAS G12C mutation and does not affect wild-type KRAS.

Immune synergy: In animal models, sotoraxib can increase CD8+ T cell infiltration in the tumor microenvironment and enhance the efficacy of PD-1 inhibitors.

Overcoming drug resistance: For drug resistance caused by activation of the EGFR signaling pathway, combining anti-EGFR antibodies (such as panitumumab) can significantly improve the efficacy.

xa0

7. Clinical efficacy and latest research progress

1. Non-small cell lung cancer: a new standard for second-line treatment

Data released in 2025 show that the 5-year survival rate of sotoraxib monotherapy for KRAS G12C mutated NSCLC is 18%, which is significantly higher than the 5% in the chemotherapy group. In addition, its combination with the PD-L1 inhibitor atezolizumab is being evaluated in phase III trials and is expected to become a new first-line treatment option.

2. Colorectal cancer: Combination therapy shows power

In the CodeBreaK 300 trial, the median PFS of the sotoraxib + panitumumab group was 2.1 months longer than that of standard treatment, without significantly increasing toxicity. The 2025 NCCN guidelines have listed it as the preferred option for KRAS G12C mutated mCRC.

3. Pancreatic cancer: Breaking through the treatment dilemma

In theKRYSTAL-7 trial, the ORR of sotorasib combined with chemotherapy in the treatment of KRAS G12C mutated pancreatic cancer reached 33.3%, with a median PFS of 5.4 months, providing new hope for this type of patients with extremely poor prognosis.

xa0

xa0

8. Domestic introduction prospects and policy discussions

Sotoraxibu has not yet been officially launched in the country, but it has attracted a lot of attention. It may be introduced in the future through clinical trials, special approvals or medical insurance negotiations. In terms of policy, the introduction of innovative drugs usually involves approval acceleration, price negotiation and medical insurance coverage assessment. For KRAS G12C targeted drugs, medical insurance coverage may alleviate patients’ financial pressure and improve accessibility. If domestic patients need it, they can obtain it through overseas drug purchase or clinical trials, but they need to pay attention to laws, regulations and safety.

xa0

Overseas reference links

https://www.amgen.com/newsroom/press-releases/2025/01/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12cmutated-metastatic-colorectal-cancer

https://en.wikipedia.org/wiki/Sotorasib

https://www.nature.com/articles/s41591-025-03732-5

https://ascopubs.org/doi/10.1200/JCO.22.02524

https://synapse.patsnap.com/article/amgen-criticized-for-profit-driven-lumakras-dosing